Investing.com - Achieve Life Sciences (NASDAQ:ACHV) reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Achieve...
Achieve Life Sciences (ACHV) reported Q3 EPS of ($1.35), $0.22 worse than the analyst estimate of ($1.13).
For Immediate ReleaseChicago, IL – November 29, 2018 - Stocks in this week’s article include: Asbury Automotive Group Inc. (NYSE:ABG) , OncoGenex Pharmaceuticals Inc. ...
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
|Average||25.125 (+813.64% Upside)|
|No. of Analysts||8|